Operating Margin % is calculated as Operating Income divided by its Revenue. MEI Pharma's Operating Income for the
three
months ended in Dec. 2023 was $-11.93 Mil. MEI Pharma's Revenue for the
three
months ended in Dec. 2023 was $0.00 Mil. Therefore, MEI Pharma's Operating Margin % for the quarter that ended in Dec. 2023 was 0.00%.
Good Sign:
MEI Pharma Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for MEI Pharma's Operating Margin % or its related term are showing as below:
MEIP'
s Operating Margin % Range Over the Past 10 Years
Min: -1762.39 Med: -173.65 Max: 21.86
Current: 21.86
MEIP's Operating Margin % is ranked better than 90.16% of 1026
companies
in the Biotechnology industry
Industry Median: -175.525
vs MEIP: 21.86
MEI Pharma's 5-Year Average Operating Margin % Growth Rate was 43.50% per year.
MEI Pharma's Operating Income for the
three
months ended in Dec. 2023 was $-11.93 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $15.88 Mil.
MEI Pharma Operating Margin % Historical Data
The historical data trend for MEI Pharma's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's Operating Margin %
For the Biotechnology subindustry, MEI Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's Operating Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's Operating Margin % distribution charts can be found below:
* The bar in red indicates where MEI Pharma's Operating Margin % falls into.
MEI Pharma Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
MEI Pharma's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEI Pharma (NAS:MEIP) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
MEI Pharma Operating Margin % Related Terms
Thank you for viewing the detailed overview of MEI Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 